Genmab A/S (NASDAQ:GMAB) vs. Organigram (NASDAQ:OGI) Head-To-Head Analysis

Genmab A/S (NASDAQ:GMAB) and Organigram (NASDAQ:OGI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Genmab A/S and Organigram’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genmab A/S	30.74%	18.90%	16.83%
Organigram	-188.38%	-40.19%	-34.70%

Analyst Recommendations

This is a breakdown of recent ratings for Genmab A/S and Organigram, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	3	1	8	0	2.42
Organigram	0	0	2	0	3.00

Genmab A/S currently has a consensus target price of $49.50, indicating a potential upside of 86.30%. Given Genmab A/S’s higher probable upside, equities analysts plainly believe Genmab A/S is more favorable than Organigram.

Valuation & Earnings

This table compares Genmab A/S and Organigram’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$17.78 billion	0.99	$631.91 million	$1.20	22.14
Organigram	$161.08 million	1.17	-$184.34 million	($0.94)	-1.93

Genmab A/S has higher revenue and earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 34.6% of Organigram shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 0.1% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Genmab A/S has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Summary

Genmab A/S beats Organigram on 10 of the 14 factors compared between the two stocks.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

About Organigram

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.